Pediatrix Medical Group, Inc. (MD)

In the past six months, Pediatrix Medical Group reported its second-quarter 2025 results with earnings of $0.46 per share and authorized a share repurchase program of up to $250 million. The company reported strong third-quarter 2025 financial results, with an adjusted EPS of $0.67, surpassing analyst expectations, which led to a significant jump in the stock price. As of February 5, 2026, the closing stock price was $20.83, and the average 12-month stock price forecast from analysts is $21.00.

Demand for Pediatrix Medical Group's services exhibits some seasonality. NICU admissions tend to be highest during the winter months, correlating with seasonal variations in general birth rates. Demand for maternal-fetal medicine specialists is increasing due to a rise in high-risk pregnancies and workforce shortages. Pediatric infectious diseases also exhibit seasonal patterns, influencing demand for pediatric subspecialty care.

Pediatrix Medical Group, Inc. is a physician-led national medical group specializing in women's and children's healthcare services. The company focuses on neonatal care, maternal-fetal medicine, and pediatric subspecialty care. Established in 1979, it has strategically expanded and refocused on its core mission.

Pediatrix Medical Group operates in 36 states across the United States, partnering with nearly 400 hospitals. Approximately 4,400 affiliated clinicians provide services across this national network, treating patients in 42 states and billing for services in 37 states.

Pediatrix Medical Group's brand reputation has been shaped by its strategic refocus on patient-centric care and operational efficiency. The company emphasizes its mission to provide excellent patient care and invests in research, education, quality-improvement, and safety initiatives. No specific events negatively impacting the company's brand reputation were found within the past year.

Pediatrix Medical Group, Inc. is predominantly controlled by institutional investors, who hold over 93% of the shares. Major institutional shareholders include BlackRock, Inc. and The Vanguard Group Inc. Company insiders hold about 5.70% of the shares, while retail investors hold the remaining 1.21%.